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A number of bacterial polysialic acids were injected intravenously into mice. Half-lives (up to 40 hf in the blood circulatron were dependent on 
the polysialic acid used, increased by deacylation of their phospholipid moiety, decreased with shorter chain derivatives and appeared to be dose 
independent. A model drug (fluorescein) covalently coupled to a polysialic acid was found to assume the half-life of its carrier. Results suggest 
that intact or deacylated polysialic acids and shorter chain derivatives can be used to augment he half-lives of drugs, small peptides, proteins and 
drug delivery systems in the blood circulation, thus prolonging their pharmacological action, 
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1. INTRODUCTION 
There are many instances where optimal use of drugs 
requires their extended presence within the vascular sys- 
tem or in extravascular areas [I]. For example. some 
antibiotics and cytostatics and a variety of peptides and 
proteins including hormones, cytokines, enzymes, anti- 
bodies and haemoglobin (as a blood surrogate) are ex- 
creted or removed from the circulation rapidly and be- 
fore therapeutic concentrations in target areas can be 
achieved. Such drugs may be more effective, less toxic 
and also used in smaller quantities if their presence in 
the blood circulation (and hence interaction with corre- 
sponding receptors or substrates intravascularly or ex- 
travasc~arly) could be prolonged [2,3]. Similarly, in- 
creased half-lives of drug delivery systems such as li- 
posomes [4], other colloidal systems [5], polymers [S] 
and antibodies [6] would facilitate targeting of drugs to 
cells other than those (e.g. the reticuloendothelial sys- 
tem; RES) by which many of these systems are normally 
intercepted [4,5]. 
Attempts to increase the half-lives of a number of 
short-lived proteins have been made successfully by 
coating these with low molecular weight (7.50-5,000) 
monomethoxypoly(ethyleneglyco1) (mPEG). Liposom- 
es and polystyrene microspheres coated with mPEG 
[7-101 or poioxamers [I 1,121 have also exhibited in- 
creased half-lives. It has been suggested [3] that mPEG 
action in prolonging the circulation time of proteins and 
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particles is due to the formation of a shell of mPEG 
molecules around their surface which sterically hinders 
interaction with factors responsible for their clearance. 
Here we report on an alternative type of macromole- 
cules which could serve to increase the circulation time 
not only of small peptides and conventional drugs (a 
role which low molecular weight mPEG, known [3] to 
be excreted rapidly through the kidneys, is unlikely to 
fulfill) but also of larger proteins, other biopolymers 
and particles. Such macromolecules are the naturally 
occurring polymers of N-acetyl neuraminic acid 
(NeuNAc) (referred to here as polysialic acids) and in- 
clude the serogroup B capsular polysaccharide from 
Neisseria meningitidis B and Escherichia coli Kl, the 
serogroup C capsular polysa~cha~de C from N. 
~eningitidis C, and the polysaccharide IS92 from E. coli 
K92 (Fig. 1) as well as their shorter chain derivatives. 
The highly hydrophilic nature of polysialic acids (Fig. 
1) and the absence of a known receptor in the body for 
NeuNAc suggested [13] that polysialic acids may exhibit 
long half-lives in the blood circulation. Results show 
that half-lives (up to 40 h) in the blood circulation of 
intravenously injected mice depend on the polysialic 
acid used. can be further increased by deacylation of the 
phospholipid moiety, decrease with shorter chain deriv- 
atives of a given polysialic acid and appear to be dose 
independent. Further, a model drug, fluorescein, co- 
valently linked to a polysialic acid assumes the half-life 
of the latter. It is proposed that intact and deacylated 
polysialic acids as well as shorter chain derivatives can 
be used to augment the half-lives of drugs, peptides, 
proteins and drug delivery systems (to which polysialic 
acids are linked) thus prolonging their pha~acologi~al 
action. A preliminary account of this work has been 
presented elsewhere [141. 
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Fig. 1. (A) Serogroup B capsular polysialic acid B (PSB) from N. 
meningitidis or E. coli Kl is a homopolymer (n = 199) of a-(2-8)- 
linked N-acetyl neuraminic acid. (B) Serogroup C capsular polysialic 
acid (PSC) from N. meningitidis C is a homopolymer (n = 74) of 
a-(2-9)-linked N-acetyl neuraminic acid; R’: H or AC. (C) Polysialic 
acid (PSK92) from E. coli K92 is a heteropolymer (n = 78) of alternate 
units of a-(2-8)-a-(2-9)-linked N-acetyl neurammic acid. All three 
polysialic acids contain a phospholipid molecule covalently linked to 
the reducing end of the polymers. 
2. MATERIALS AND METHODS 
N. meningitidis B polysaccharide B (PSB) (average chain length 199 
NeuNAc units), N. meningitidis C polysaccharide C (PSC) (average 
chain length 74 NeuNAc units) and E. co11 K92 polysaccharide 
(PSK92) (average chain length 78 NeuNAc units) were prepared as 
previously described [l&16]. Their degree of acylation was determined 
[17] and found to be 66%. 20% and 37%, respectively. Fluorescem as 
such (sodium salt) or in its isothiocyanate form (FITC) were from 
Sigma (London). All other reagents were of analytical grade. 
2.1. Deacylation of the phospholipid moiety of polysiahc acids 
Solutions of PSB, low molecular weight PSB (82 NeuNAc units), 
PSC and PSK92 in 0.1 M NaOH (typically 10 mg/ml) were incubated 
at 37°C for 4 h [17] and subsequently dialyzed exhaustively against 
phosphate-buffered saline (Buffer) composed of 0.44 mM sodium 
phosphate, 2.7 mM potassium chloride and 0.14 M sodium chloride. 
pH 7.4. Deacylated polysialic acids were used within 24 h of their 
preparation. 
2.2. Preparation of the polysialrc acid-fluorescein conjugate 
Fluorescein was covalently coupled to PSB as described previously 
[18]. Briefly, PSB was dissolved in dimethylsulphoxide as the tetrabu- 
tyl ammonium salt and stirred in the presence of FITC for 24 h at 
room temperature. Uncoupled FITC was removed by sequential dial- 
ysis against 0.1 M ammonium acetate, pH 9, precipitation of the PSB 
with 3 ~01s. of ethanol, followed by gel filtration through Sephadex 
G-25 and a second ethanol precipitation step before freeze-drying. 
PSB had a degree of substitution of 0.009 (i.e. 9 molecules of dye per 
lo3 molecules PSB) and an average chain length of 82 NeuNAc units 
[17]. The PSB-fluorescein conjugate was radiolabelled with “‘1 as 
previously described [19]. 
2.3. Assay of polymeric N-acetyl neuraminic acid 
Diluted blood samples (see later) were centrifuged at 3,000 rpm for 
10 min to remove blood cells. Supernatants containing the plasma 
were mixed with trichloroacetic acid (8% final concentration), kept at 
4°C for 1 h and then centrifuged at 3,000 rpm for 10 min to precipitate 
native plasma protein-bound NeuNAc. Supernatants as well as other 
polysialic acid samples were assayed for NeuNAc by the method of 
Svennerholm [20]. Estimation of NeuNAc was carried out on the basis 
of standard curves made with each of the polysialic acids used, appro- 
priately diluted either in Buffer or in blood plasma from intact mice. 
In preliminary work it was established that NeuNAc values m the 
blood plasma (after trichloroacetic acid precipitation) of mice taken 
before treatment were nil. 
2.4. Assay offluorescem 
Fluorescein in diluted plasma samples (see later) was assayed 
fluorometrically at excitation and emission wavelengths of 482 and 
512 nm, respectively. Values were estimated from a standard curve 
made with appropriately diluted plasma containing varying amounts 
of added dye. 
2.5. Animal experiments 
Male T.O. (Clinical Research Centre) mice weighing 25-30 g were 
injected into the tail vein with 0.104.25 ml Buffer containing PSB, 
PSC or PSK92 (l-2 mg per mouse) either in their intact or fully 
deacylated form. In some experiments mice were injected with 0.25 ml 
Buffer containing various amounts of low molecular weight PSB co- 
valently coupled to “SI-labelled fluorescein, or fluorescein only. Ani- 
mals were bled from the tail vein at time intervals and blood (typically 
50 ~1) was placed into 0.5 ml Buffer for the same assay of NeuNAc. 
“‘I-radioactivity or fluorescein. 
3. RESULTS AND DISCUSSION 
3.1. Polysialic acid clearance from the circulation 
The clearance pattern of PSB from the blood circula- 
tion of injected mice was biphasic with 50% of the dose 
removed 3 min after injection (Fig. 2). The remainder 
assumed a linear rate of clearance with a half-life of 20 
h. PSB, as well as PSC and PSK92, in solution have a 
phospholipid moiety covalently attached through its 
phosphate group to their reducing end [21] (Fig. 1). As 
a result, polysialic acids exhibit micellar behaviour and 
form aggregates [21]. The PSB used here was partially 
deacylated (see section 2) probably because of long- 
term storage, and only the acylated remainder would be 
expected to form aggregates. This would explain the 
partial rapid loss of PSB from the circulation (Fig. 2). 
Hydrolysis of the acyl groups (e.g. by alkali treatment) 
abolishes the slightly hydrophobic nature of the acyl- 
ated molecules, leads to their deaggregation and per- 
haps a slower rate of clearance. Fig. 2 shows that this 
is indeed the case; only 5-10% of the fully deacylated 
PSB was removed rapidly, the remainder exhibiting a 
linear rate of clearance with a half-life of 30 h. As in the 
case of PSB, clearance of PSC, was initially rapid with 
nearly 70% of the injected dose removed within 3 min 
(Fig. 3) even though PSC was only 20% acylated (see 
section 2). Thereafter, removal was slower. Surpris- 
ingly, a considerable amount (about 50%) of the fully 
deacylated PSC was initially also cleared rapidly, the 
remainder assuming a linear pattern with a half-life of 
20 h (Fig. 3). It should be noted, however, that in the 
conditions of deacylation there is a concomitant hydrol- 
ysis of the O-acetyl groups of carbons 7 and/or 8 (Fig. 
1) of PSC, an event which could have contributed to the 
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Fig. 2. Clearance of PSB from the blood circulation. In six separate xperiments, mice in groups of 3-4 animals were injected intravenously with 
1.1-2.0 mg of intact (0) or deacylated (e) PSB and bled at time intervals. NeuNAc in the blood plasma samples was assayed as described in section 
2 and expressed as 6 r S.D. of the dose in total blood. (Values from a11 groups treated with intact and deacylated PSB, respectively, were pooled.) 
Blood volume was estimated as 7% of the body weight [9]. For other details see the text. 
0 10 20 30 40 50 
Time (hours) after injection 
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Fig. 3. Clearance of PSC from the blood circulation. Mice in two groups of 5 were injected intravenously with 2 mg of intact (0) or deacylated 
(0) PSC. For other details see legend to Fig. I. 
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rapid clearance of deacylated PSC. On the other hand, 
there was no apparent difference in the clearance pat- 
terns of PSK92 before and after full deacylation (Fig. 
4). Following a relatively slow clearance during the first 
6 h, patterns became linear, with half-lives of 40 h. 
Similar results were observed in a second identical ex- 
periment performed with the same batch of PSK92 
(data not shown). 
Results in Figs. 24 thus suggest that the rate of 
removal of a given polysialic acid from the circulation 
is dependent on the presence or absence of phospholipid 
acyl groups. It also appears to depend on the structure 
of polysialic acids, since the a-(2-9)-linked PSC is 
cleared more rapidly than the a-(2-g)-linked PSB or the 
a-(2-8)-ol-(2-9)-linked PSK92. Further as the chain 
lengths of the three polysialic acids are an average, the 
preparations are polydisperse. Therefore, the presence 
of lower molecular weight moieties may contribute to 
the early rapid removal of much of the polysialic acid 
from the circulation, particularly for PSC which has a 
lower average chain length (74) than PSB ( 199 NeuNAc 
units). In this respect, experiments with PSB of short 
chain length (15 NeuNAc units) have revealed (data not 
shown) that over 90% of the injected dose is removed 
from the circulation within 30 min. This, however, is not 
sufficient to explain the intriguing result with PSK92, 
which has an average chain length (78 NeuNAc units) 
no higher than PSC, yet is not removed rapidly from 
circulation, whether intact or deacylated. It suggests 
that factors other than chain length and aggregation of 
polysialic acids are also important in determining circu- 
latory half-life. 
3.2. Clearance of a model drug bound to polysialic acid 
Prolonged circulation of the polysialic acids studied, 
prompted us to investigate the extent to which a model 
drug (fluorescein) covalently coupled to polysialic acid. 
a low molecular weight deacylated PSB (82 NeuNAc 
units), would assume the half-life of its carrier. Data in 
Fig. 5 show that clearance of coupled fluorescein 
(which, as such, is removed from the circulation very 
rapidly (Fig. 5). is independent of the dose of injected 
PSB for the amounts tested. Following the removal of 
about 80% of the dose within 2.5 h, the remainder ex- 
hibited a half-life of 5 h, presumably that of the conju- 
gate. Since the limit of sensitivity of the NeuNAc assay 
in the blood plasma would not allow the monitoring of 
NeuNAc values for doses lower than 0.5 mg PSB per 
mouse in this experiment, only NeuNAc values from 
mice injected with the higher doses of deacylated PSB 
are shown (Fig. 5). These values are similar to those 
corresponding to conjugated fluorescein, further sup- 
porting the view that fluorescein is cleared in conjunc- 
tion with its carrier. A similar half-life (5.5 h) was ob- 
tained with the intact PSB-FITC conjugate (results not 
shown), probably because the proportion of molecules 
of the low molecular weight intact PSB (derived from 
the larger molecular weight PSB; 199 NeuNAc units) 
0 4 8 12 16 20 24 
Time (hours) after injection 
Fig. 4. Clearance of PSK92 from the blood circulation. Mice in two groups of 4 were injected intravenously with 1.8 mg of intact (0) or deacylated 
(0) PSK92. For other details see legend to Fig. I. 
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Fig. 5. Clearance of low molecular weight fluorescein-PSB conjugate from the blood circulation. Mice in groups of three were injected intravenously 
with 28 (v), 102 (m), 510 (A) and 1,528 pg (0) of PSB conjugated to [‘*‘I]fluorescein or with 40 pg fluorescein only (0). Values are means f S.D. 
of ‘251-radioactivity (closed symbols), NeuNAc (0) or fluorescein. Stars denote the mean of “‘1 mean values for all doses at each time interval. 
For other details see legend to Fig. 1. 
that would contain a phospholipid moiety would be too 
low to contribute to significant aggregation and a 
shorter half-life. 
In conclusion, polysialic acids such as those described 
here, could potentially retain rapidly cleared drugs 
within the vascular and extravascular areas for pro- 
longed periods of time. Because of the dependence of 
clearance rates of polysialic acids not only on the type 
used and the state of their phospholipid (intact or de- 
acylated). but also on the molecular size (compare Figs. 
2 and 5), it would be possible to tailor clearance rates 
of drugs to satisfy specific needs. It is envisaged that 
large molecular weight polysialic acids would be suita- 
ble for the delivery of one or more molecules of small 
molecular weight drugs and peptides. Shorter chain pol- 
ysialic acids, on the other hand (derived by autohy- 
drolysis of long-chain molecules), could be used to coat 
large proteins as well as drug delivery systems such as 
liposomes. Conjugation of drugs and liposomes to pol- 
ysialic acids could be carried out by a variety of meth- 
ods, depending on the reactive groups available on the 
interacting entities. Possible sites of conjugation in pol- 
ysialic acids include the non-reducing end which, on 
periodate oxidation, would generate a reactive alde- 
hyde, the carboxyl and hydroxyl groups, and the amino 
groups becoming available on deacetylation (Fig. 1). 
However, caution is required as coupling reactions 
could potentially damage the tertiary structure of the 
longer chain polysialic acid and thus, possibly, alter 
their clearance patterns. 
Polysialic acids have the advantage of being biode- 
gradable and catabolic products (e.g. NeuNAc) are not 
known to be toxic. Furthermore, polysialic acids, like 
other polysaccharides, are T-independent antigens and 
do not induce immunological memory. For instance, 
PSB is non-immunogenic in animals and humans which 
has hampered attempts to produce a vaccine against N. 
meningitidis group B or E. coli Kl [22]. Although PSC 
and PSK92 have been shown to be immunogenic in 
humans, it is necessary to use polysaccharides with mo- 
lecular weights in excess of 50,000 Da (average chain 
length greater than 170 NeuNAc units) [21]. This. how- 
ever, is not true when considering polysialic acids cou- 
pled to proteins. Here, polysialic acids can become T- 
cell dependent antigens with induction of memory, and 
no restriction on the size of the polymer applies. None- 
theless, immune responses are difficult to achieve (espe- 
cially for PSB) although immunogenic vaccines have 
been manufactured by coupling polysialic acids to some 
protein carriers [18,22,24]. Another, perhaps more im- 
portant, consideration in selecting a polysialic acid as 
a drug carrier, is antigenicity (i.e. binding of the antigen 
to its antibodies). Although it has been shown that anti- 
bodies against some of the polysialic acid structures 
examined here exist at low levels in circulation, they are 
generally of low affinity, especially against cr-(228)- 
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linked PSB [25]. Indeed, c&(2-8)-linked sialic acid struc- 
tures are known to be present on host cell surfaces, 
thereby limiting any immunological response [26]. Fi- 
nally, taking into account the pathogenicity of N. me- 
ningitidis it would be easier, from the practical point of 
view, to produce polysialic acids from slightly or non- 
pathogenic bacteria. Since PSB (deacylated) and PSK92 
exhibit the longest half-lives (Figs. 2 and 4) and can be 
derived from the slightly pathogenic E. co/i Kl (PSB) 
and the non-pathogenic E. coli K92 (PSK92) bacteria, 
these materials and their hydrolysis lower molecular 
weight products should be adopted for conjugation to 
drugs and drug delivery systems. 
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